SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. SGLT2 inhibitors are clinically effective in halting DKD progression. However, the underlying mechanisms remain unclear. The serum and kidneys of mice with DKD were analyzed using liquid chromatography wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yong-Ping, Zhang, Ze-Yu, Wu, Hong-Wei, Fang, Li-Jing, Hu, Bo, Tang, Chun, Zhang, Yi-Qing, Yin, Lianghong, Tang, Dong-E., Zheng, Zhi-Hua, Zhu, Ting, Dai, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476562/
https://www.ncbi.nlm.nih.gov/pubmed/36104729
http://dx.doi.org/10.1186/s12967-022-03629-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476562/
https://www.ncbi.nlm.nih.gov/pubmed/36104729
http://dx.doi.org/10.1186/s12967-022-03629-8

Ejemplares similares